Tasosartan

Tasosartan

Clinical data
Pregnancy category	N/A
ATC code	C09CA05 (WHO)
Legal status
Legal status	Withdrawn
Identifiers
IUPAC name 2,4-dimethyl-8-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one
CAS Number	145733-36-4
PubChem (CID)	60919
IUPHAR/BPS	6898
DrugBank	DB01349
ChemSpider	54890
UNII	48G92V856H
Chemical and physical data
Formula	C23H21N7O
Molar mass	411.459 g/mol
(what is this?)  (verify)

Tasosartan is an angiotensin II receptor antagonist.

It was withdrawn from FDA review by the manufacturer after phase III clinical trials showed elevated transaminases (a sign of possible liver toxicity) in a significant number of participants given the drug.^[1][2]

References

1. Atkinson AJ, et al. (2007). Principles of clinical pharmacology. Amsterdam: Elsevier. p. 515. ISBN 0-12-369417-5.
2. Dina R, Jafari M (July 2000). "Angiotensin II-receptor antagonists: an overview". Am J Health Syst Pharm. 57 (13): 1231–41. PMID 10902066.